Last reviewed · How we verify
Aspirin and/or Atorvastatin
Aspirin and/or Atorvastatin is a Antiplatelet agent and HMG-CoA reductase inhibitor (statin) Small molecule drug developed by NYU Langone Health. It is currently FDA-approved for Secondary prevention of cardiovascular events (myocardial infarction, stroke), Primary prevention of cardiovascular disease in high-risk patients.
Aspirin inhibits platelet aggregation via COX inhibition, while atorvastatin reduces cholesterol synthesis by inhibiting HMG-CoA reductase, together reducing cardiovascular risk.
Aspirin inhibits platelet aggregation via COX inhibition, while atorvastatin reduces cholesterol synthesis by inhibiting HMG-CoA reductase, together reducing cardiovascular risk. Used for Secondary prevention of cardiovascular events (myocardial infarction, stroke), Primary prevention of cardiovascular disease in high-risk patients.
At a glance
| Generic name | Aspirin and/or Atorvastatin |
|---|---|
| Sponsor | NYU Langone Health |
| Drug class | Antiplatelet agent and HMG-CoA reductase inhibitor (statin) |
| Target | Cyclooxygenase (COX) and HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Aspirin irreversibly inhibits cyclooxygenase (COX), preventing thromboxane A2 synthesis and platelet aggregation, thereby reducing thrombotic events. Atorvastatin competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, lowering LDL cholesterol and reducing atherosclerotic plaque formation. This combination addresses both thrombotic and lipid-related mechanisms of cardiovascular disease.
Approved indications
- Secondary prevention of cardiovascular events (myocardial infarction, stroke)
- Primary prevention of cardiovascular disease in high-risk patients
Common side effects
- Gastrointestinal bleeding or ulceration (aspirin)
- Muscle pain or myalgia (atorvastatin)
- Elevated liver enzymes (atorvastatin)
- Dyspepsia
- Rhabdomyolysis (rare)
Key clinical trials
- Atorvastatin Pretreatment in Cerebrovascular Events (APICES) After Flow Diverter Implantation (PHASE4)
- Women's IschemiA TRial to Reduce Events In Non-ObstRuctive CAD (PHASE4)
- Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease (PHASE3)
- A EUROpean Randomized Study on Blood-thinners and Cholesterol-lowering Treatments to Prevent Future Vascular Events in People With Covert Brain Infarcts (CBI) (PHASE3)
- Cognitive Decline and Underlying Mechanisms in Symptomatic Intracranial Artery Stenosis Patients: A Cohort Study
- Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study (PHASE4)
- Atorvastatin ± Aspirin in Lynch Syndrome Syndrome (EARLY_PHASE1)
- Secondary Prevention of Cardiovascular Disease in the Elderly Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aspirin and/or Atorvastatin CI brief — competitive landscape report
- Aspirin and/or Atorvastatin updates RSS · CI watch RSS
- NYU Langone Health portfolio CI
Frequently asked questions about Aspirin and/or Atorvastatin
What is Aspirin and/or Atorvastatin?
How does Aspirin and/or Atorvastatin work?
What is Aspirin and/or Atorvastatin used for?
Who makes Aspirin and/or Atorvastatin?
What drug class is Aspirin and/or Atorvastatin in?
What development phase is Aspirin and/or Atorvastatin in?
What are the side effects of Aspirin and/or Atorvastatin?
What does Aspirin and/or Atorvastatin target?
Related
- Drug class: All Antiplatelet agent and HMG-CoA reductase inhibitor (statin) drugs
- Target: All drugs targeting Cyclooxygenase (COX) and HMG-CoA reductase
- Manufacturer: NYU Langone Health — full pipeline
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Secondary prevention of cardiovascular events (myocardial infarction, stroke)
- Indication: Drugs for Primary prevention of cardiovascular disease in high-risk patients
- Compare: Aspirin and/or Atorvastatin vs similar drugs
- Pricing: Aspirin and/or Atorvastatin cost, discount & access